{"url_path":"/sec/mntr/10-q/2026/item-1","section_key":"item-1","section_title":"Item 1 Legal Proceedings.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1599117/0001493152-26-022905-index.html","accession_number":"0001493152-26-022905","cik":"0001599117","ticker":"MNTR","issuer_name":"Mentor Capital, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1599117/0001493152-26-022905-index.html","primary_entity_key":"0001599117","primary_entity_name":"Mentor Capital, Inc."},"word_count":786,"has_tables":true,"body_markdown":"Item 1. Legal Proceedings.\n\n \n\nG FarmaLabs Limited\n\n \n\nOn August 27, 2021, the Company and Mentor Partner\nI settled certain litigation with G FarmaLabs Limited, a Nevada corporation, and certain of its affiliates (the “G Farma Settlors”).\nThe G Farma Settlors partially performed, and then breached, the Settlement Agreement.\n\n \n\nConsequently, in February 2023, the Company and Mentor\nPartner I filed a Request for Entry of Judgment seeking entry of a stipulated judgment against the G Farma Settlors for (1) the remaining\nunpaid settlement amount of $494,450 promised, all accrued and unpaid interest thereon, and an additional $2,000,000 principal amount\nas agreed in the Settlement Agreement, (2) the Company’s incurred costs, and (3) attorneys’ fees paid by the Company to obtain\nthe judgment. On July 11, 2023, the Court entered judgment against the G Farma Settlors and in favor of Mentor and Partner I in the amount\nof $2,539,597, which is comprised of $2,494,450 of principal (calculated as the aggregate settlement amount, less payments made by the\nG Farma Settlors, plus the default addition) plus accrued and unpaid interest of $40,219, costs of $1,643, and attorneys’ fees of\n$3,285 incurred by Mentor and Mentor Partner I in connection with obtaining the judgment. The judgment also accrues post-judgment interest\nat the rate of 10% from July 11, 2023, until such time as the judgment is paid in full.\n\n \n\n-34-\n\n \n\n \n\nThe Company has retained the reserve on the unpaid\nnotes receivable balance and collections of the unpaid lease receivable balance due to the history of uncertain payments from G Farma\nand the G Farma Settlors. Payments recovered will be reported as Other income in the consolidated income statements. See Notes 1, 4, and\n7 to this Quarterly Report and Notes 1, 8, 9, and 16 to Company’s Annual Report for the period ended December 31, 2024 on Form 10-K\nfiled with the Securities and Exchange Commission on March 31, 2025. The $2,539,597 judgment and interest receivable of $691,605 for the\nthree months ended March 31, 2026 is fully reserved pending the outcome of the Company’s collection process.\n\n \n\nInvestment in account receivable\n\n \n\nOn April 10, 2015, the Company entered into an exchange\nagreement whereby the Company received an investment in an account receivable with annual installment payments of $117,000 for 11 years\nthrough 2026, totaling $1,287,000 in exchange for 757,059 shares of Mentor Common Stock obtained through the exercise of 757,059 Series\nD warrants at $1.60 per share plus a $0.10 per warrant redemption price.\n\n \n\nThe Company valued the transaction based on the market\nvalue of Company common shares exchanged in the transaction, resulting in a 17.87% discount from the face value of the account receivable\nor net present value of $0.78 per share, the then current share price closing. The discount is being amortized monthly to interest over\nthe 11-year term of the agreement. In the fourth quarter of 2020, we were notified that due to the effect of COVID-19, we might not receive\nthe 2020 installment or the full 2021 installment. Based on management’s collection estimates, we recorded an investment loss of\n($139,148) on the investment in account receivable at December 31, 2020. In 2021, the Company re-evaluated estimated collections and recorded\nan investment gain of $22,718. Subsequently, on February 15, 2022, the terms of the investment were modified, resulting in an additional\nloss of ($41,930). The loss of ($41,930) and gain of $22,718 were reflected in Other Income on the consolidated income statement for the\nyears ended December 31, 2022 and 2021, respectively.\n\n \n\nOn January 10, 2023, the Company received the 2023\nannual installment payment of $117,000. Three additional $117,000 annual installment payments were due in early 2024, 2025, and 2026.\nThe 2024 and 2025 annual installment payments have not been received.\n\n \n\nOn June 11, 2024, our investment in account receivable\nwas impaired by $250,208. The $250,208 impairment consisted of the Company’s estimate of the reduction of $287,200 purchased receivable\noffset by a ($36,992) purchased receivable discount. The Company’s recognition of an impairment loss due to the uncertainty of collection\ndoes not diminish its contractual rights to collect the full amounts due pursuant to the contract. For the years ended December 31, 2025\nand 2024, $0 and $9,559 of discount amortization are included in interest income.\n\n \n\nThe Company was notified by the originating third-party\npayor of the $1,287,000 account receivable that the Company purchased from the former payee that, in or about December 2025 the third-party\npayor intended to deposit a $180,000 payment with the Superior Court of California, County of Fresno, in an interpleader action through\nwhich Mentor and the former payee could resolve ownership of the $180,000. The Company has obtained legal counsel in Fresno, and it is\ncurrently pursuing the $180,000 in an interpleader action."}